Action HLUN B H. LUNDBECK A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues H. Lundbeck A/S

Actions

HLUN B

DK0061804770

Temps réel estimé Cboe Europe
Autres places de cotation
 16:24:03 28/06/2024 		Varia. 5j. Varia. 1 janv.
39,07 DKK +2,55% Graphique intraday de H. Lundbeck A/S +0,52% +18,74%
26/06 Le traitement du SSPT d'Otsuka et de Lundbeck progresse, la FDA ayant accepté la demande d'autorisation de mise sur le marché d'un nouveau médicament MT
25/06 La FDA américaine accepte la demande de nouveaux médicaments de Lundbeck et d'Otsuka pour le traitement combiné du stress post-traumatique MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment
Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder
Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial
Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia
H LUNDBECK : Q1 beat adds momentum to the recent share price rally
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024
H LUNDBECK : Lundbeck is well-poised to sail through the transition period
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Lundbeck : Articles of Association
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HLUN B
  4. Actualités H. Lundbeck A/S
  5. Autres langues